Daily choices of functional foods supplemented with milled flaxseed by a patient population over one year

2016 ◽  
Vol 26 ◽  
pp. 772-780 ◽  
Author(s):  
J. Alejandro Austria ◽  
Michel Aliani ◽  
Linda J. Malcolmson ◽  
Elena Dibrov ◽  
David P. Blackwood ◽  
...  
Keyword(s):  
Patient Population ◽  
Functional Foods ◽  
One Year ◽  
Milled Flaxseed

A Study of Violent Behaviour Among In-Patients in a Psychiatric Hospital

1986 ◽  
Vol 149 (2) ◽  
pp. 232-235 ◽  
Author(s):  
Mark Pearson ◽  
Elizabeth Wilmot ◽  
Madhu Padi
Keyword(s):  
Retrospective Analysis ◽  
Psychiatric Hospital ◽  
Patient Population ◽  
Violent Behaviour ◽  
Violent Incident ◽  
One Year ◽  
Almost All

A retrospective analysis of the violent incident forms returned over a one year period in a psychiatric hospital recorded 283 incidents involving 144 patients. Almost all were of a petty nature, none leading to lasting injuries. Compared with the average daily in-patient population, offending patients were more likely to be male, to be less than 45 years old, and to have a diagnosis of schizophrenia.

Mental health care in the community: an evaluative study

1975 ◽  
Vol 5 (4) ◽  
pp. 372-380 ◽  
Author(s):  
B. Cooper ◽  
B. G. Harwin ◽  
C. Depla ◽  
Michael Shepherd
Keyword(s):  
Mental Health ◽  
Health Care ◽  
Social Worker ◽  
Patient Population ◽  
Control Group ◽  
Group Practice ◽  
Evaluative Study ◽  
Therapeutic Value ◽  
The Status ◽  
One Year

SynopsisA study was designed to assess the therapeutic value of attaching a social worker to a metropolitan group practice in the management of chronic neurotic illness. The psychiatric and social status of a group of patients before treatment and after one year was compared with the status of a control group treated more conventionally over the same period. The results indicate that the experimental service conferred some benefit on the patient population.

Sorafenib In Combination with Standard Induction and Consolidation Therapy In Elderly AML Patients: Results From a Randomized, Placebo-Controlled Phase II Trial

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 333-333 ◽  
Author(s):  
Hubert Serve ◽  
Ruth Wagner ◽  
Cristina Sauerland ◽  
Uta Brunnberg ◽  
Utz Krug ◽  
...  
Keyword(s):  
Overall Survival ◽  
Phase Ii ◽  
Patient Population ◽  
Phase Ii Trial ◽  
Consolidation Therapy ◽  
Standard Chemotherapy ◽  
Treatment Groups ◽  
Elderly Aml ◽  
Grade 3 ◽  
One Year

Abstract Abstract 333 Background: Standard chemotherapy for elderly AML patients results in a median overall survival of only about one year. Case reports and early phase I/II data have shown that the kinase inhibitor Sorafenib might show clinical benefit for Flt3-ITD-positive AML patients (Metzelder S Blood 2009; 113:6567) and that its addition to standard chemotherapy is feasible (Ravandi F JCO 2010; 28:1856). Sorafenib is a potent Raf, c-Kit and FLT3 inhibitor that may also affect AML blasts and bone marrow (BM) stroma cells via VEGFR and PDGFR-β inhibition. Therefore, we performed a multicenter, randomized, placebo-controlled, double-blind phase II trial in elderly (>60 y) AML patients analyzing the effect of Sorafenib in addition to standard chemotherapy and as a maintenance therapy for up to one year. Methods: 197 AML patients in 16 centers received up to two cycles of standard 7+3 induction chemotherapy plus two cycles of consolidation therapy with intermediate dose (6 × 1g/sqm) AraC. Before start of treatment, they were randomly assigned to receive either placebo or Sorafenib (400 mg bid between the cycles and after chemotherapy for up to one year after start of induction). The primary aim was to compare the event-free survival (EFS) of the two treatment groups. Secondary end points were to compare EFS and overall survival (OS) of predefined subgroups according to NPM and FLT3 mutation status and toxicity of treatment. Results: Among the 197 evaluable patients, 102 pts received Sorafenib and 95 pts placebo. EFS and OS were not significantly different between the two treatment groups (placebo vs. Sorafenib: EFS: Median: 7 vs. 5 months, hazard Ratio (HR): 1.261(p=0.13); OS: Median: 15 vs. 13 months, HR 1.025 (p=0.89)). CR or blast clearance without complete blood count recovery was observed in 49 (48%) and 9 (8.8%) Sorafenib patients and 57 (60%) and 4 (4.2%) placebo pts, respectively. Exploratory subgroup analyses did not reveal any significant difference between the treatment groups but showed a tendency towards decreased EFS in the Sorafenib arm for NPM1-wild type AML cases. Flt3-ITD mutations were found in 28 out of 197 patients (14.2%), in line with the reported incidence in the target population. No differences in EFS or OS were to be noted in this small patient population. Also, CR rate was not improved by the study drug in this subgroup of patients. Sorafenib was relatively well tolerated. The most frequent adverse events (AE) ≥grade 3 were febrile neutropenia, pneumonia in neutropenia, sepsis, diarrhea, skin rash, mucositis, hypertension (77 vs 74, 54 vs 35, 15 vs 15, 17 vs 6, 14 vs 7, 9 vs 6, 8 vs 5 events in the Sorafenib vs the placebo group). A hand-foot-skin reaction (≥grade 3) was noted in 5 vs 0 events in Sorafenib vs control pts. There was a trend of slower regeneration of leukocytes and thrombocytes within the Sorafenib arm compared to the control arm after the first and second induction course but not after consolidation cycles. Conclusion: Although the combination regimen appeared to be feasible and tolerable in elderly AML pts, Sorafenib treatment did not improve EFS or OS in this unselected elderly AML patient population. Further studies should focus on selected AML target populations for Sorafenib, especially FLT3-ITD+ AML patients. Disclosures: Off Label Use: Sorafenib (multikinase inhibitor) is given in combination with standard chemotherapy in elderly AML patients. (See title of the abstract!).

Treating nonagenarians with cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 8542-8542
Author(s):  
E. J. Crane ◽  
M. Extermann
Keyword(s):  
General Anesthesia ◽  
Cancer Patients ◽  
Patient Population ◽  
Treatment Plan ◽  
Performance Status ◽  
Cancer Center ◽  
Preliminary Evaluation ◽  
Ecog Performance Status ◽  
Patients Âgés ◽  
One Year

8542 Background: In the U.S., the number of cancer patients who are greater than age 85 is expected to quadruple in the next 50 years. Barriers exist to treating this patient population because of concerns of frailty, lack of inclusion in clinical trials, and unknown outcomes when treating this patient population. This single institution retrospective evaluation provides data regarding treatment outcomes for cancer patients ages 90 or older at the time of their treatment at this cancer center. Methods: The charts of all patients registered at the Moffitt Cancer Center who were age 90 or older at during their treatment/evaluation were eligible to be reviewed. The total number of charts eligible was 643. Included patients: 1) had a diagnosis of cancer, 2) had a clear treatment plan with at least two follow-up visits over a one month time period, 3) patients with only one evaluation would be eligible if a clear treatment plan was outlined and their death occurred within 6 months of their evaluation at this cancer center. To date, 329 charts have been reviewed which has yielded 121 patients who meet the inclusion criteria. Results: Preliminary evaluation of reveals that the most common diagnoses are breast cancer (14%), malignant melanoma (11%), head and neck cancer (9%), SCC of the skin (9%), and prostate cancer (8%). Treatment plans included surgery for 45% of the patients with 36% of the patients undergoing general anesthesia. Chemotherapy was administered to 6.8% of the patients, and hospice was recommended to 7.8%. One year after evaluation at this cancer center 54% of the patients were alive, and 42% were alive at 2 years. The average number of medications that these patients used was 5.5 and greater than 95% of the patients had an ECOG performance status of 1. Conclusions: These preliminary results indicate that the nonagenarian cancer patients are probably healthy given the low number of medications taken, indicating fewer comorbid conditions. These patients do have months to years of survival after their therapies which included surgery under general anesthesia and chemotherapy. Although the nonagenarian cancer patient population found at a referral center is likely to be healthier than that found in the community, these findings indicate that nonagenarians with few comorbidities and a good performance status can be successfully treated for their cancer. No significant financial relationships to disclose.

scholarly journals Cluster headache in childhood and adolescence: one-year prevalence in an out-patient population

2003 ◽  
Vol 4 (3) ◽  
pp. 132-137 ◽  
Author(s):  
Beatrice Gallai ◽  
◽  
Giovanni Mazzotta ◽  
Francesca Floridi ◽  
Alessia Mattioni ◽  
...  
Keyword(s):  
Cluster Headache ◽  
Patient Population ◽  
Childhood And Adolescence ◽  
One Year

The New Chronics

1967 ◽  
Vol 113 (498) ◽  
pp. 555-556 ◽  
Author(s):  
Ralph V. Magnus
Keyword(s):  
Patient Population ◽  
Number Of Patients ◽  
One Year

There have been two surveys of the patient population of Glenside Hospital, Bristol, in recent years—Cooper and Early (1961), and Early and Magnus (1966). Since the 1961 review, a considerable number of patients admitted have become “chronic”, i.e. have remained continuously in hospital for over one year. An attempt to enquire into this problem has been made.

Abstract 16054: Medical Management and Outcomes of Non-obstructive Coronary Artery Disease

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Sarah Payne ◽  
Ethan Fry ◽  
Jeffrey Michel ◽  
Robert J Widmer
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Statin Therapy ◽  
Cardiac Catheterization ◽  
Patient Population ◽  
Obstructive Coronary Artery Disease ◽  
Angiotensin Ii Receptor Blocker ◽  
Ed Visits ◽  
Artery Disease ◽  
One Year

Introduction: Non-obstructive coronary artery disease (NOCAD) is associated with increased morbidity and higher medical expenses compared to those without NOCAD. Currently there are no set guideline-directed interventions for this patient population. This study examined the management and subsequent cardiovascular (CV) events in those deemed to have NOCAD. Hypothesis: We hypothesized that maximal use of medical therapy would correlate with reduced events. Methods: We undertook a retrospective chart review of 1,752 patients who underwent cardiac catheterization from 10/23/2017 through 10/24/2018 at a tertiary care center. NOCAD was defined as patients underwent cardiac catheterization for ischemic symptoms/testing, but did not receive percutaneous coronary or surgical intervention, were not pre-operative, and had at least one year of follow-up post-catheterization. We obtained medications at the time of catheterization as well as subsequent CV testing and events including hospitalizations and emergency department (ED) visits. Results: Of the 168 patients diagnosed with NOCAD, 12 patients later suffered a CV event including NSTEMI, heart failure exacerbation, or stroke. Of these patients, 41.7% were not been placed on aspirin, statin, beta-blocker (BB), calcium channel blocker (CCB), aldactone, ACE inhibitor (ACEi), or angiotensin II receptor blocker (ARB). In NOCAD patients on statin therapy there was a reduced utilization of CV testing at one year (43.3% vs 58.7%, p=0.04). Furthermore we note a significant reduction in rehospitalizations and ED visits in those on statin (14.5% vs 29.4%, p=0.02) not seen in patients on aspirin (23.8% vs 20.6%, p=0.63), CCB (22.2% vs 25.0%, p=0.76), aldactone (36.7% vs 19.6%, p=0.05), ACEi/ARB (23.1% vs. 22.2%, p=0.90), and even note a significant increase in events in those on BB (30.3% vs 16.3%, p=0.03). Conclusions: While NOCAD is associated with increased morbidity and healthcare utilization, the initiation of statin appears to reduce future CV testing and rehospitalization/ED visits that is not noted with aspirin, BB, CCB, Aldactone, or ACEi/ARB use. Recognition of NOCAD, and initiation of statin therapy could be beneficial in this patient population.

scholarly journals Universal Germline Testing of Unselected Cancer Patients Detects Pathogenic var Iants Missed by Standard Guidelines without Increasing Healthcare Costs

Cancers ◽  
2021 ◽  
Vol 13 (22) ◽  
pp. 5612
Author(s):  
Adrienne T. Perkins ◽  
Derrick Haslem ◽  
Jessica Goldsberry ◽  
Katherine Shortt ◽  
Laura Sittig ◽  
...  
Keyword(s):  
Genetic Testing ◽  
Cancer Patient ◽  
Cancer Patients ◽  
Patient Population ◽  
Healthcare Costs ◽  
Cost Of Care ◽  
Cancer Types ◽  
One Year ◽  
Current Guidelines ◽  
Pan Cancer

Purpose: To accurately ascertain the frequency of pathogenic germline variants (PGVs) in a pan-cancer patient population with universal genetic testing and to assess the economic impact of receiving genetic testing on healthcare costs. Methods: In this prospective study, germline genetic testing using a 105-gene panel was administered to an unselected pan-cancer patient population irrespective of eligibility by current guidelines. Financial records of subjects were analyzed to assess the effect of PGV detection on cost of care one year from the date of testing. Results: A total of 284 patients participated in this study, of which 44 patients (15%) tested positive for a PGV in 14 different cancer types. Of the patients with PGVs, 23 patients (52%) were ineligible for testing by current guidelines. Identification of a PGV did not increase cost of care. Conclusion: Implementation of universal genetic testing for cancer patients in the clinic, beyond that specified by current guidelines, is necessary to accurately assess and treat hereditary cancer syndromes and does not increase healthcare costs.

Sign in / Sign up

Export Citation Format

Share Document